Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
Background: Many pediatric inflammatory bowel disease (IBD) patients are now using biosimilars of anti-tumor necrosis factor-α (TNF-α), with increasing trends in recent years. This study reviewed all available data regarding the use of biosimilars in children with IBD.Methods: PubMed, Google Scholar...
Saved in:
Main Authors: | Valeria Dipasquale (Author), Giuseppe Cicala (Author), Edoardo Spina (Author), Claudio Romano (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children
by: Valeria Dipasquale, et al.
Published: (2022) -
Dysbiosis in the Pathogenesis of Pediatric Inflammatory Bowel Diseases
by: Donatella Comito, et al.
Published: (2012) -
Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
by: Fang Wang, et al.
Published: (2023) -
Surgery-Related Quality of Life of Pediatric Patients With Crohn's Disease
by: Valeria Dipasquale, et al.
Published: (2020) -
Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
by: Zhen Zeng, et al.
Published: (2024)